Orchestra BioMed wins FDA IDE for sirolimus-angioballoon
April 29, 2025
Orchestra BioMed (Nasdaq:OBIO) announced today that it received FDA investigational device exemption (IDE) for its Virtue drug-coated balloon.
Orchestra BioMed (Nasdaq:OBIO) announced today that it received FDA investigational device exemption (IDE) for its Virtue drug-coated balloon.
A judge has issued a permanent injunction, signaling an Insulet (Nasdaq:PODD) victory in a trade secret case against EOFlow.
Dr. Ho Sang Jung and his research team from the Advanced Bio and Healthcare Materials Research Division at the Korea Institute of Materials Science (KIMS), in collaboration with Seoul St. Mary’s Hospital, have developed a technology that enables the diagnosis of osteoarthritis and rheumatoid arthritis within 10 minutes using synovial fluid. This marks the first such achievement in Korea.
The circuits could help researchers develop new treatments for fragile X syndrome and other diseases caused by mutations of a single gene.
William Blair analyst Brandon Vazquez said 2025 could be the first year market leader Intuitive Surgical will face meaningful U.S. competition.
A study on donor lungs preserved outside the body before transplantation demonstrated that the hypothermic oxygenated machine perfusion (HOPE) technique is a safe and effective lung preservation method, even with total out-of-body times approaching 20 hours.
Medtronic (NYSE: MDT) announced that it received FDA approval for its OmniaSecure defibrillation lead for right ventricle placement.
Clarius is the first to offer an FDA-cleared AI-powered prostate measurement tool on a handheld ultrasound scanner—empowering primary care and urology physicians to assess patients on the spot without waiting for specialist referrals
Researchers from the PRODI Center for Protein Diagnostics at Ruhr University Bochum, Germany, and the biotech company betaSENSE have now discovered a biomarker in the spinal fluid that facilitates a reliable diagnosis at an early stage and can shed light on the progression of the disease and the effect of a therapy. They report their findings in the journal EMBO Molecular Medicine from April 25, 2025.
New studies offer insight into disease’s treatment, lingering symptoms